Enhanced Ocular Delivery Systems and Methods for Schlemm's Canal Treatment

The inventive concept discloses advanced ocular delivery systems and methods for treating eye conditions, particularly glaucoma, by optimizing the delivery of viscoelastic fluid compositions into Schlemm's canal, utilizing real-time feedback from sensors monitoring intraocular pressure.

The original patent described systems and methods for accessing Schlemm's canal in an eye, delivering a fluid composition, and performing a trabeculotomy. However, the original patent had limitations in terms of flow control, real-time monitoring, and adaptability. The new inventive concept addresses these limitations by incorporating advanced features, such as controllers, sensors, and optimized flow rates, to ensure efficient and safe treatment.

The inventive concept comprises a fluid delivery system with an elongate member, a reservoir containing a viscoelastic fluid composition, and a controller configured to regulate the flow of the fluid composition through the elongate member. The system also includes sensors to monitor intraocular pressure, providing real-time feedback to the controller, which adjusts the flow rate accordingly. This enables optimized delivery of the fluid composition into Schlemm's canal, ensuring effective treatment of glaucoma and other eye conditions.

The new claims introduce the concept of real-time feedback from sensors monitoring intraocular pressure, which allows for adaptive flow control and optimized delivery of the viscoelastic fluid composition. This is a significant advancement over the original patent, which lacked such features.

Alternative embodiments may include variations in sensor types, controller algorithms, and fluid composition properties. Additionally, the inventive concept could be adapted for use in other ocular procedures, such as cataract surgery or retinal treatments.

The enhanced ocular delivery systems and methods have significant commercial potential in the ophthalmology market, particularly for glaucoma treatment. The target industries include medical device manufacturers, ophthalmic clinics, and pharmaceutical companies.